Immunome, Inc. (IMNM) vs NewAmsterdam Pharma Company N.V. (NAMS)
Immunome, Inc. and NewAmsterdam Pharma Company N.V. are both Biotechnology companies. Immunome, Inc. and NewAmsterdam Pharma Company N.V. are of similar size ($2.7B and $2.6B). Immunome, Inc. grew revenue faster over the last twelve months: 16.7% against −88.9%. Immunome, Inc. has the higher net margin (0.00% vs −3,644.2%) and the lower return on invested capital (−3,323.0% vs 0.00%). Across the 15 metrics below, Immunome, Inc. leads on 8 and NewAmsterdam Pharma Company N.V. on 7.
Valuation
Profitability
| Metric | IMNM | NAMS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (3,432.20%) | 0.00% |
| Net margin | 0.00% | (3,644.21%) | 0.00% |
| Free cash flow margin | 0.00% | (2,018.28%) | 0.00% |
| Return on equity | (64.03%) | (36.81%) | (57.72%) |
| Return on assets | (59.03%) | (34.16%) | (49.22%) |
| Return on invested capital | (3,322.99%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack